• 디지털융복합연구
• /
• 제11권1호
• /
• pp.299-308
• /
• 2013

TCDD 독성이 유발된 흰쥐 혈액의 생화학적 지표에 미치는 상엽 물추출물 (MLE)의 효과를 조사하였고 통계자료는 일원분산분석과 Scheffe의 사후검증을 하였다. TCDD 투여 시 감소했던 백혈구와 혈소판의 수가 MLE투여로 급격하게 회복(p<0.01)되어 면역기능 개선효과가 있었다. TT에 의해 감소했던 혈중 칼슘 및 마그네슘의 농도는 MLE 투여 시 유의하게 증가(p<0.01)하였으나 인의 농도는 TT군에 비하여 MLE군이 유의하게 감소(p<0.01)하였다. 신장 기능과 관련된 creatinine 및 blood urea nitrogen은 TT군과 MLE군 사이에 유의성은 없었으며, 요산은 TT군과 MLE군 모두에서 감소하였다. 한편 TT에 의해 증가했던 glucose 농도, amylase 및 lipase의 효소 활성도는 MLE 투여시 유의하게 감소(p<0.01)하여 혈당상승 억제효과가 있었다. Total protein, ${\gamma}$-GTP 활성은 TT와 MLE의 영향을 거의 받지 않았으나 TT에 의해 증가했던 AST, ALT 및 ALP의 활성도는 MLE 투여 시 모두 유의하게 감소(p<0.01)하여 간기능 개선의 효과가 있었다. 한편 Total cholesterol, triglyceride와 LDL-cholesterol의 경우 TT에 의해 유발된 고지혈 증상이 MLE 투여 시 유의하게 감소(p<0.01)하여 항고지혈 효과가 있었으며 HDL-cholesterol은 TT군과 MLE군 모두에서 증가하였다. 이와 같이 MLE는 TCDD독성이 유발된 흰쥐에서 독성을 완화시켜 주는 작용이 있음을 알 수 있었다.

• 대한임상독성학회지
• /
• 제12권2호
• /
• pp.92-96
• /
• 2014

Dabigatran is the first oral direct thrombin inhibitor approved by the US Food and Drug Administration (FDA) for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Because dabigatran is excreted mainly by the kidneys, serum levels of dabigatran can be elevated to a supratherapeutic range in patients with renal failure, predisposing to emergent bleeding. We describe the case of a 66-year-old man taking dabigatran 150 mg twice daily for atrial fibrillation and cerebral infarction who presented with hematochezia and disseminated intravascular coagulation. Laboratory evaluation showed a hemoglobin level of 6.3 g/dL, platelets of $138,000/mm^3$, activated partial thromboplastin time (aPTT) of 10 s, and an international normalized ratio (INR) of 8.17. Colonoscopy showed a bleeding anal fissure. Hemostasis was provided by hemoclips and packed red blood cells and fresh frozen plasma were transfused. Since then, there was no further hematochezia, however, bleeding including oral mucosal bleeding, hematuria, and intravenous site bleeding persisted. At presentation, his serum creatinine was 4.96 mg/dL (baseline creatinine, 0.9 mg/dL). Dabigatran toxicity secondary to acute kidney injury was presumed. Because acute kidney injury of unknown cause was progressing after admission, he was treated with hemodialysis. Fresh frozen plasma transfusion was provided with hemodialysis. At 15 days from admission, there was no further bleeding, and laboratory values, including hemoglobin, partial thromboplastin time, and prothrombin time were normalized. He was discharged without bleeding. After 2 months, he undergoes dialysis three times per week and no recurrence of bleeding has been observed.

• 한국식품위생안전성학회지
• /
• 제8권1호
• /
• pp.37-53
• /
• 1993

옥수수에 자연 발생하는 F. monliforme MRC 826을 옥수수에 배양하여 배양물에 존재하는 fumonisin $B_{1}$을 정성검사 한 후, 배양물질의 독성 및 발암성을 aflatoxin $B_{1}$과 비교하여 보았다. 독성 시험은 3주령의 Sprague-Dawley(SD) 암컷 랫드 10마리를 각 군당 5마리씩 2개 군으로 나누어 제1군은 시험 군으로 배양물질을 분말사료와 1 : 1로 혼합하여 1주간 급여하였고, 제 2군은 대조군으로 분말사료만을 급여하면서 실험하였다. 시험군은 급여 3~4일경부터 침울해 보였으며, 랫드 1마리당 1주간 평균 사료 섭취량은 24 g이었고, 평균 체중은 18 g 감소하였다. 부검 시 신장의 피막박리가 곤란하였고 조직 검사 결과 간장의 공포변성에 신장 세뇨관 상피세포의 괴사등의 관찰되었다. 발암성 검사 6주령의 SD 수컷 랫드 70마리를 사용하여 중기 발암성 검색법인 diethylnitrosamine-partial hepatectomy (DEN-PH) 모델로 시험하였다. 시험군은 각 군당 14마리씩 총 5개군을 두었으며 실험 0일 때 DEN을 복상내로 투여하였고, 2주후에 제 1군(양성대조군)은 aflatoxin $B_{1}$을 2ppm 농도로 첨가한 사료를, 제4군 옥수수를 5% 농도로 첨가한 사료를, 제 5군은 옥수를 2.5% 농도로 첨가한 사료를 각각 6주간 급여하였다. 실험 3주간에 간 부분 절제술을 시술하였고, 8주간 체중변화, 사료섭취량 음수량을 측정한 후 부검하여 간장은 glutathione S-transferase placental form (GST-P) 면역조직화학적 염색을 실시하였고, 뇌, 뇌하수체, 융선, 폐, 부신, 신장, 심장, 비장, 정낭선, 고환 및 간장 등은 H&E 염색을 하여 병변을 관찰하였다. GST-P 염색결과 5% 배양물질 투여군은 aflatoxin $B_{1}$투여군과 유사하게 GST-P 양성병소의 발현율이 대조군에 비하여 유의성 있는 증가를 보였다. 5% 배양물질 투여군 및 2.5% 배양물질 투여군은 옥수수 투여군에 비하여 증체율의 저하가 관찰되었고, 5% 배양물질 투여군에서 간, 신장, 고환 및 정낭선등의 체중에 대한 상대중량비, 혈액요소질소와 평균 적혈구 혈색소량 등은 옥수수 투여군에 비하여 유의성 있는 변화가 관찰되었다. 이상의 결과들을 종합해 볼 때 F. monliforme MRC 826 배양물질은 랫드의 간과 신장에 독성을 나타내었고, aflatoxin $B_{1}$과 마찬가지로 간암 촉진효과가 있는 것으로 판단되었다.

• 한국환경보건학회지
• /
• 제20권2호
• /
• pp.64-72
• /
• 1994

Tolerance to toxic effects of cadmium (Cd), including lethality has been shown following pretreatment with cadmium and zinc. This study was designed to determine if tolerance also develops to Cd-induced hepatotoxicity and renal toxicity. Three groups of rats (A, B, C), each consisting of 108 rats, were studied and each group was divided into three subgroups (1, 2, 3), 12 rats for each subgroup. Rats were subcutaneously pretreated with saline (A), CdCl$_2$ (0.5 mg/kg, B), and ZnCl$_2$ (13.0 mg/kg, C) during time periods of 5 days. At the end of the period, rats were challenged with CdCIa (3.0 and 6.0 mg/kg) by intraperitoneal injection. As for the cadmium levels in rat tissues after pretreatments, it was highest in the liver. Then kidney, heart, blood and muscle followed it in that order. After 24, 48 and 96 hours of intraperitoneal injection by challenge doses the concentration of cadmium in liver and kidney increased proportionally to the increase of challenge dosage. However metallothioneins in liver and kidney were increased by the pretreatment of cadmium and zinc. These data indicate the liver is a major target organ of acute Cd poisoning, and suggest that cadmium induced hepatic injury, via release of Cd-MT, may play and important role in the nephrotoxicity observed in response to short-term exposure to cadmium. This result suggests that increasing cadmium concentrations, gradually accumulating in liver and kidney as the result of the pretteatmerit, served to induced the synthesis of metallothionein, thus making them resistant to the challenge from cadmium.

• 약학회지
• /
• 제36권6호
• /
• pp.591-597
• /
• 1992

The organ distribution of $[^3H]$-methotrexate-lactosaminated bovine serum albumin conjugates ($[^3H]$-MTX-LBSA) was investigated to examine their role as a liver-specific anticancer drug. Synthesis of lactosaminated bovine serum albumin(LBSA) with BSA, lactose and sodium cyanoborohydride through reductive amination was followed by its conjugation with methotrexate (MTX) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), thereby synthesizing [$[^3H]$-MTX-LBSA conjugates. Organ distribution and plasma elimination profiles were studied in male Wistar rats after intravenous injection of [$[^3H]$-MTX-LBSA conjugates. The fates of $[^3H]$-MTX and the $[^3H]$-MTX-BSA conjugates´fates were also investigated for comparison. The results showed that the plasma level of $[^3H]$-MTX-LBSA conjugates declined more rapidly than those of $[^3H]$-MTX-BSA and their liver concentration was significantly higher than those of other treatment (p<0.01). In addition, their uptake compared to the amount taken up by the liver (1 : 33.1 at 10 min, 1 : 24.1 at 120 min). All these suggested that MTX-LBSA conjugate is one of the drug delivery system (DDS) that is advanced in concentrating MTX in the liver and minimizing the renal toxicity of MTX.

• Toxicological Research
• /
• 제14권3호
• /
• pp.365-370
• /
• 1998

To evaluate the renal toxicity of the antitumor agent, p-{N,N,-Bis(2-chloroethyl)amino}-4-phenyl acetyl-amino-2,6-piperidinedione(CK-15), rats were treated with CK-15 (acute: 50mg/kg. i.p., single and subacute: 5mg/kg, i.p., daily for 7 days). The changes in the body weight, water consumption, kidney weights and urine volume after and during the treatment were observed. The concentrations of urinary creatinine and portein, the activities of N-acetyl-${\beta}$-D-glucosaminidase (NAG), alanine aminopeptidase (AAP), ${\gamma}$-glutamyl transpeptidase (${\gamma}$-GT) and lactate dehydrogenase (LDH) in 24hr urine were also determined. The body weight, water consumption, and urine volume were decreased after the acute and subacute administration. However the weights of kidney were not changed after the treatments. The excretion of creatinine was significantly decreased 1 day after acute administration but, returned to the control value. In subactute administration, the excretion of creatinine was gradually decreased. However, the protein excretion did not changed in both treatment. Those indicate that CK-15 might decrease the metabolic rate of muscle. THe urinary activities of NAG, AAP, ${\gamma}$-GT, and LDH were significantly affected bythe drug treatment. The urinary activities of NAG, AAP and ${\gamma}$-GT were significantly increased 1 day after the acute administration and then returned to the control value. However, the urinary activities of LDH were not changed in acute treatment. In subacute treatment, although the urinary activities of NAG were not changed, those of AAP and ${\gamma}$-GT were significantly increased 2.3 times at 3 days during the subacute administration. Also the urinary activities of LDH were significantly increased at 7 day after the administration. These results indicate that the high and subacute administration might induce a damage in the kidney cells. Furthermore the present results suggest that the toxic effects of CK-15 might be due to the accumulation of the metabolites.

• Toxicological Research
• /
• 제14권3호
• /
• pp.415-425
• /
• 1998

A recombinant human erythropoietin (rHuEPO) was administered intravenously at dosage levels of 0, 100, 500, and 2500IU/kg/day for a period of 3 weeks. There were no observed clinical signs and deaths related to treatment in all groups tested. Decreases in body weight gain and food consumption were observed only in males of 2,5000IU/kg group after 2 weeks. In hematological parameters, erythrocyte content, hematocrit values and hemoglobin concentration were dose- dependently increased in rHuEPO treated groups. The ratio between kidney weight and whole body weight was significantly increased in females of 500 and 2,500IU/kg groups. The spleen weight was also increased in both sexes of 500 and 2,500IU/kg groups. However, the absolute weight change of other organs was not observed. In histopathological examinations, the renal tubular basophilia was observed only in males and females of 2,500IU/kg groups. From these results, it is concluded that the no-observed adverse effect level (NOAEL) of rHuEPO is 100 IU/kg in rats in the present study.

• Biomolecules & Therapeutics
• /
• 제13권2호
• /
• pp.65-77
• /
• 2005

Present article reviews about clinical pharmacology of mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF), as widely used component of immunosuppressive regimens in the organ transplantation field. MMF, used alone or concomitantly with cyclosporine or tacrolimus, has approved in reducing the incidence of acute rejection and has gained widespread use in solid organ such as kidney, heart and liver transplantation. The application of MPA and development of MMF has shown a considerable impact on immunosuppressive therapy for organ transplantation as a new immunosuppressive agent with different mechanism of action from other drugs after early 1990s. In particular aspect, use of MMF, a morpholinoethyl ester of MPA, represented a significant advance in the prevention of organ allograft rejection as well as allograft and patient survival. In considering MMF clinical data, it is important to note that there is a strong correlation between high MPA area under curve(AUC) values and a low probability of acute allograft rejection. Individual trials have shown that MMF is generally well tolerated and revealed that MMF decreased the relative risk of developing chronic allograft rejection compared with azathioprine. Recent clinical investigations suggested that improved effectiveness and tolerability will results from the incorporation of MPA therapeutic drug monitoring into routine clinical practice, providing effective MMF dose individualization in renal and heart transplant patients. Therefore, MMF has a selective immunosuppressive effect with minimal toxicity and has shown to be more effective that other agents as next step of immunosuppressive agents and regimens that deliver effective graft protection and immunosuppression along with a more favorable side effect.

• 생약학회지
• /
• 제38권2호통권149호
• /
• pp.123-127
• /
• 2007

Aristolochic acid (AA) included in the plants Aristolochiaceae have been well known to be nephrotoxic and carcinogenic inducer and to cause renal disease such as Chinese Herb Nephropathy (CHN). In this study, we used a high performance liquid chromatopaphy-mass spectrometry (HPLC-MS) under the positive ion detection mode for the quantitative change of aristolochic acid-I and-II (AA-I and AA-II) in Aristolochiaceae (Aristolochia contorta Bunge, Aristolochia debilis Sieb. et Zucc., Aristolochia fangchi Wu), some related plants (Cocculus trilobus De candolle, Inula helenium Linne, Saussurea lappa Clarke), and its prescriptions (防己茯笭湯, 定喘散) with or without processing. Here, the processing methods and prescriptions in oriental medicine were generally used to alleviate toxicity or alter property of herbal medicines. However, the concentrations of AA-I and AA-II were highly determined in processed material extracts rather than unprocessed those, not measured in some related plants. Also, the concentrations of AA-I and AA-II even at the prescriptions mixed the plants of Aristolochiaceae were detected to range from 0.73 to 2.53 ppm. Thus, the present results suggest that the content of AA-I and AA-II contained to plants of Aristolochiaceae was not reduced by the processing methods or prescriptions which can induce the physico-chemical change and pharmacological transformation in traditional herbal medicines.

• 한국환경보건학회지
• /
• 제23권1호
• /
• pp.81-94
• /
• 1997

The concentrations of cadmium, metallothionein(MT), superoxide dismutase(SOD), and lactate dehydrogenase(LDH) were investigated in liver and kidney of rats which were fed the water containing 50 or 100ppm cadmium chloride with basal diet(group A), 5% horsetail diet(group, B), 5% mugwort diet(group C) and 5% champignon diet(group D) for weeks. Cadmium in liver decreased for the first 12 weeks of treatment, but thereafter increased, and was lower in experimental group B,C,D than in control group A. Cadmium in kidney increased linearly during the 16 weeks of treatment, and was lower in group B than in group A. MT in liver decreased for the first 12 weeks of treatment in group A, but increased linearly during the 16 weeks in group B,C,D, higher in group B than in group A. There were significantly higher accumulation of cadmium and MT in liver than in kidney in the beginning of cadmium treatment, but reversed in the ending of treatment. The SOD and LDH activities were not affected during the 16 weeks treatment, and there was no significant difference between groups. Histologic examination revealed moderate to severe hepatic and renal injury in group A compared to horsetail diet group B. These results indicate that the kidney is a major target organ of chronic cadmium poisoning, and suggest that Cd-induced hepatic injury, via release of Cd-MT, may play an important role in the nephrotoxicity. In addition, higher MT concentrations in liver and kidney in the group B constitute a plausible explanation of the protective effects of horsetail diet against the cadmium toxicity in relation to histologic findings.